saffron for attention deficit hyperactivity disorder in adults

Saffron (crocus sativus) for attention deficit hyperactivity disorder in adults: a double blind and placebo controlled trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20090117001556N111

Enrollment

Registered

2018-07-25

Start date

2018-08-05

Completion date

Unknown

Last updated

2018-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Disturbance of activity and attention. Attention-deficit hyperactivity disorders

Interventions

Intervention 1: Intervention group: Capsule saffron 15 mg BID plus Tab. ritaline ( methylphenidate) 30 mg per day for 6 weeks. Intervention 2: Control group: Capsule placebo plus tab. ritaline ( methy

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Diagnosis of ADHD based on DSM-5 Age between 20-60 years old

Exclusion criteria

Exclusion criteria: Chronic medical disease including seizure, cardiovascular disease, CVA and organic brain disease Substance abuse or dependence during past six months Nursing or pregnant patients History of tic disorder Receiving of any psychotropics drugs during past two weeks, Intellectual disability History of suicide attempt, psychosis or aggressiveness Receiving psycho-stimulants or atomoxetine during past three months Bipolar disorder

Design outcomes

Primary

Measure	Time frame
Severity of ADHD. Timepoint: Baseline (before treatment) and weeks: 3 and 6 after treatment. Method of measurement: By adult ADHD Self-Report Scale and Conners Adult ADHD Rating Scales–Self-Report-screening version.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactProf. Shahin Akhondzadeh

Tehran University of Medical Sciences

s.akhond@sina.tums.ac.ir+98 21 5541 2222

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026